Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:0
|
作者
T D Gould
J A Quiroz
J Singh
C A Zarate
H K Manji
机构
[1] Laboratory of Molecular Pathophysiology,
[2] National Institute of Mental Health,undefined
来源
Molecular Psychiatry | 2004年 / 9卷
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
暂无
中图分类号
学科分类号
摘要
Bipolar disorder afflicts approximately 1–3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:21
相关论文
共 41 条
  • [31] A limit cycle oscillator model for cycling mood variations of bipolar disorder patients derived from cellular biochemical reaction equations
    Frank, T. D.
    COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION, 2013, 18 (08) : 2107 - 2119
  • [32] Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application
    C C Watkins
    A Sawa
    M G Pomper
    Translational Psychiatry, 2014, 4 : e350 - e350
  • [33] Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application
    Watkins, C. C.
    Sawa, A.
    Pomper, M. G.
    TRANSLATIONAL PSYCHIATRY, 2014, 4 : e350 - e350
  • [34] The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades
    Drago, Antonio
    Crisafulli, Concetta
    Sidoti, Antonina
    Calabro, Marco
    Serretti, Alessandro
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 190 : 429 - 438
  • [35] Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial
    Garriga, Marina
    Sole, Eva
    Gonzalez-Pinto, Ana
    Selva-Vera, Gabriel
    Arranz, Belen
    Amann, Benedikt L.
    Saiz-Ruiz, Jeronimo
    Perez-Blanco, Josefina
    Vieta, Eduard
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (10) : 959 - 969
  • [36] Causal dynamics of sleep, circadian rhythm, and mood symptoms in patients with major depression and bipolar disorder: insights from longitudinal wearable device data
    Song, Yun Min
    Jeong, Jaegwon
    de los Reyes, Aurelio A.
    Lim, Dongju
    Cho, Chul-Hyun
    Yeom, Ji Won
    Lee, Taek
    Lee, Jung -Been
    Lee, Heon-Jeong
    Kim, Jae Kyoung
    EBIOMEDICINE, 2024, 103
  • [37] Molecular and cellular basis of obsessive-compulsive disorder-like behaviors: emerging view from mouse models
    Yang, X. William
    Lu, Xiao-Hong
    CURRENT OPINION IN NEUROLOGY, 2011, 24 (02) : 114 - 118
  • [38] Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling
    Jawa, Yashika
    Yadav, Pooja
    Gupta, Shruti
    Mathan, Sivapar V.
    Pandey, Jyoti
    Saxena, Ajay K.
    Kateriya, Suneel
    Tiku, Ashu B.
    Mondal, Neelima
    Bhattacharya, Jaydeep
    Ahmad, Shandar
    Chaturvedi, Rupesh
    Tyagi, Rakesh K.
    Tandon, Vibha
    Singh, Rana P.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [39] Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials
    Bai, Yuanhan
    Liu, Tiebang
    Xu, Ahong
    Yang, Haichen
    Gao, Keming
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (08) : 703 - 717
  • [40] "Insights into molecular and cellular mechanisms of hormonal actions on fish ion regulation derived from the zebrafish model" (vol 251, pg 12, 2017)
    Guh, Ying-Jey
    Hwang, Pung-Pung
    GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2018, 259 : 240 - 240